Foamix Obtains US Patent for Iodine Foam - Innovative Treatment for Heat Burns/ Warfare Materials, as well as Fungal and Bacterial infection
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.
- (1888PressRelease) March 12, 2012 - US Patent No. 8,119,106, entitled "Foamable iodine compositions", encompasses the use of unique foam compositions comprising Iodine for treating the burns from heat and from warfare materials such as mustard gas, as well as fungal and bacterial infection.
Iodine - Natural Cure
Iodine and iodine complex preparations are widely known and employed as disinfectants in human and veterinary medicine. Iodine has a powerful bactericidal and fungicidal action and is also active against viruses.
Iodine is further effective against burns: Treatment with topical iodine preparation has been shown to provide significant protection against heat burns and burns resulting from warfare materials, such as mustard gas.1
Iodine Foam - Next Generation Cure for Warfare Threats
In times where biological and chemical warfare agents remain a serious and even growing threat. In particular, the increasing propagation of biological and chemical agents can not be ruled out due to their relatively easy production compared to nuclear agents.
Iodine Foam, which is easily applied to large skin areas, can be a simple, on-the-go treatment for burns from warfare materials such as mustard gas. Such a product will be useful not only in clinics and hospitals but also in every ambulance or military medical unit.
New topical dosage forms are desired to deliver iodine and to treat skin conditions that respond to topical iodine application. Foam offers superior usability; it absorbers evenly and easily into the skin with no need for rubbing.
"This patent paves the way for our penetration into areas outside of "pure" dermatology; and further validates the versatility and potential of our topical foam platform" remarks Dr. Dov Tamarkin, CEO of Foamix. "We plan to approach security bodies around the world with this life-saving technology."
1 Wormser et al. Arch. Toxicol. (1997) 71, 165-170; Wormser, Burns (1998) 24, 383
Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.
The Company's development capabilities range from initial development of the formulations and analytical methods to scale-up, GMP manufacturing, preclinical and clinical studies.
Foamix has a strong in-house pipeline. The Company's lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 13 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 140 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.
For additional information please see www.foamix.co.il
Dorit Hayon, Business Development Manager, Foamix Ltd., dorit ( @ ) foamix dot co dot il
Dov Tamarkin, CEO, Foamix Ltd., dov ( @ ) foamix dot co.il.